Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC

```
                reclassification data
 NEWS 30  JUN 30  AEROSPACE enhanced with more than 1 million U.S.
                  patent records
 NEWS 31  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:53:03 ON 16 JUL 2008

=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:53:14 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 JUL 2008  HIGHEST RN 1034171-01-1
DICTIONARY FILE UPDATES:  15 JUL 2008  HIGHEST RN 1034171-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-533,555-2.str



chain nodes :
10 11 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 12 15 16 17 18
chain bonds :
7-10 8-11 10-12 10-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-15 12-18 15-16 16-17 17-18

exact/norm bonds :
5-7 6-9 7-8 7-10 8-9 8-11 10-13 12-15 12-18 15-16 16-17 17-18
exact bonds :
10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:53:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      108 TO ITERATE

100.0% PROCESSED      108 ITERATIONS                                6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1537 TO     2783
PROJECTED ANSWERS:               6 TO      266

L2            6 SEA SSS SAM L1

=> d scan
```

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 5-[(4-ethyl-4-piperidinyl)amino]-2,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-, (3Z)-
MF C30 H31 N5 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 3-[3H-benzimidazol-2-yl](3-methoxyphenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)-
MF C30 H31 N5 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 3-[3H-benzimidazol-2-yl](2,5-difluorophenyl)methylene]-5-[[1-ethyl-4-piperidinyl]amino]-1,3-dihydro-, (3Z)-
MF C29 H27 F2 N5 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 3-[(2,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)-
MF C25 H25 F2 N5 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)-
MF C26 H28 F N5 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-5-[[3-(phenylmethyl)-3-pyrrolidinyl]amino]-, (3Z)-
MF C34 H33 N5 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l1 sss full
FULL SEARCH INITIATED 14:54:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      1991 TO ITERATE

100.0% PROCESSED     1991 ITERATIONS                              109 ANSWERS
SEARCH TIME: 00.00.01

L3          109 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.82     179.03

FILE 'CAPLUS' ENTERED AT 14:54:36 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Jul 2008  VOL 149 ISS 3
FILE LAST UPDATED: 15 Jul 2008  (20080715/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4            2 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:33844 CAPLUS
DOCUMENT NUMBER: 146:119982
TITLE: A subtype of non-small cell lung carcinoma (NSCLC) tumors dependent on platelet-derived growth factor receptor α and its diagnosis and treatment
INVENTOR(S): Hikova, Klarize; Polakiewicz, Roberto; Sho, Aulan; Crosby, Katherine; Song, Qingzi; Lee, Kimberly
PATENT ASSIGNEE(S): Cell Signaling Technology, Inc., USA
SOURCE: PCT Int. Appl., 99pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005027	A1	20070111	WO 2005-US23858	20050705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 20070148711	A1	20070628	US 2005-174651	20050701
AU 2005334261	A1	20070111	AU 2005-334261	20050705
CA 2617241	A1	20070111	CA 2005-2617241	20050705
EP 1907842	A1	20080409	EP 2005-769977	20050705
R: AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 20080036649	A	20080424	KR 2008-702716	20080131
PRIORITY APPLN. INFO.:			US 2005-174651 A	20050701
			WO 2005-US23858 W	20050705

AB A previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha drives the disease is identified. The receptor can be used as a marker to identify these tumors and as a target for cancer chemotherapy using PDGFRα-inhibiting drugs. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor. PDGFRα was identified as extensively phosphorylated in NSCLC cell lines. Immunoassays showed that the receptor was present in H1703 cells, but not in A549 cells. H1703 cells were sensitive to inhibition the protein tyrosine kinase inhibitor Gleevec. A survey of patients showed

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
that PDGFRα was present in 6% of NSCLC cases.

IT 918332-08-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for inhibition of growth of PDGFRα-dependent NSCLC; subtype of NSCLC tumors dependent on PDGFRα and its diagnosis and treatment)
RN 918332-08-0 CAPLUS
CN 2H-Indol-2-one, 5-[(3-ethyl-4-piperidinyl)amino]-3-[(5-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:693723 CAPLUS
DOCUMENT NUMBER: 141:54195
TITLE: Preparation of oxindole derivatives as kinase modulators
INVENTOR(S): Barnes, Lynne Canne; Brown, S. David; Cheng, Wei; Cu, Erick Wang; Nuss, John M.; Kim, Moon Kwan; Klein, Rhett Ronald; Le, Donna T.; Lew, Amy Mac; Morrison B.; Parks, Jason Jevtuov; Wen, Zhaoyang; Xu, Wei
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058681	A2	20040617	WO 2003-US38567	20031114
WO 2004058681	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2506546	A1	20040617	CA 2003-2506546	20031114
AU 2003302665	A1	20040623	AU 2003-302665	20031114
EP 1581309	A2	20051005	EP 2003-812437	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006518727	T	20060906	JP 2004-570786	20031114
US 20060122273	A1	20060608	US 2005-533555	20050502
PRIORITY APPLN. INFO.:			US 2002-426680P P	20021115
			US 2003-470674P P	20030514
			WO 2003-US38567 W	20031114
OTHER SOURCE(S):	MARPAT 141:54195			
GI				

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The title compds. I [W = N or CR1; R1 = H, halo, trihaloalkyl, CN, NH2, NO2, OR6, N=CHNR6R7, N(R6)C(=NR8)NR6R7, SR6, S(O)1-2R6, SO2NR6R7, CO2R6, etc.; L = O, S(O)0-2, or NR3; Q = C or N, when Q = N, then R4 does not exist; R2, R3 = H or R7; R4, R5 = H, OR6, NR6R7, S(O)0-2R6, SO2NR6R7, CO2R6, C(O)NR6R7, N(R6)SO2R6, NC(O)R6, C(O)R7, CN, NO2, NR2, halo, trihaloalkyl, R7; or R4, R5 when taken together, form a five or six-membered aromatic ring containing 0-2 N; R6, R7 = H, substituted(alkyl)alkyl, (substituted)heterocycloalkyl, (substituted)aryl, (substituted)heterocyclyl, with proviso or R6, R7 = when taken together with common N to which they are attached, form a five to seven-membered heterocyclic ring containing at least one addnl. heteroatom selected from N, O, S, or P; R8 = H, NO2, CN, OR6, or (substituted)alkyl; X = (substituted)(hetero)aromatic ring; R = O, S, (substituted)amino] were prepared as kinase modulators to treat kinase-dependent diseases and conditions. For example compound II was prepared in a multi-step synthesis starting from 4-methylimidazole. The latter inhibited KDR and EGFR with IC50 < 50 nM.

IT 705945-70-4P 705945-78-2P 705945-80-0P
705945-81-9P 705945-82-0P 705945-83-1P
705945-84-2P 705945-85-3P 705945-86-4P
705945-87-5P 705945-88-6P 705945-89-7P
705945-90-0P 705945-91-1P 705945-93-3P
705945-94-4P 705945-95-5P 705945-96-6P
705945-97-7P 705945-98-8P 705945-99-9P
705946-00-5P 705946-01-6P 705946-02-7P
705946-03-8P 705946-04-9P 705946-05-0P
705946-06-1P 705946-07-2P 705946-14-1P
705946-15-2P 705946-16-3P 705946-17-4P
705946-18-5P 705946-19-6P 705946-21-0P
705946-22-1P 705946-23-2P 705946-24-3P

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
705946-25-4P 705946-26-5P 705946-27-6P
705946-28-7P 705946-29-8P 705946-30-1P
705946-32-3P 705946-33-4P 705946-34-5P
705946-35-6P 705946-36-7P 705946-37-8P
705946-38-9P 705946-39-0P 705946-40-3P
705946-41-4P 705946-42-5P 705946-43-6P
705946-44-7P 705946-45-8P 705946-46-9P
705946-47-0D 705946-48-1P 705946-49-2P
705946-50-5P 705946-51-6P 705946-52-7P
705946-53-8P 705946-54-9P 705946-55-0P
705946-56-1P 705946-57-2P 705946-58-3P
705946-59-4P 705946-60-7P 705946-61-8P
705946-62-9P 705946-63-0P 705946-64-1P
705946-65-2P 705946-66-3P 705946-67-4P
705946-68-5P 705946-69-6P 705946-70-9P
705946-71-0P 705946-72-1P 705946-73-2P
705946-74-3P 705946-76-5P 705946-77-6P
705946-78-7P 705946-79-8P 705946-80-1P
705946-81-2P 705946-82-3P 705946-83-4P
705946-84-5P 705946-85-6P 705946-86-7P
705946-87-8P 705946-88-9P 705946-89-0P
705946-90-3P 705946-91-4P 705946-92-5P
705946-93-6P 705946-94-7P 706816-70-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preps. of oxindole deriva. as kinase modulators)

RN 705945-78-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-5-[[1-(phenylmethyl)-3-pyrrolidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-79-5 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-3-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 705945-83-1 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-84-2 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-85-3 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-methoxyphenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 705945-92-0 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-93-1 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)(4-methoxyphenyl)methylene]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 705945-82-0 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)(4-methoxyphenyl)methylene]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-86-4 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-ylphenylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-87-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-5-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-88-6 CAPLUS
CN 2H-Indol-2-one, 3-[(4-aminophenyl)-1H-benzimidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705945-92-2 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl(4-methoxyphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-94-4 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-95-5 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705945-96-6 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-97-7 CAPLUS
CN Benzenetitle,
3-[(E)-1H-benzimidazol-2-yl][5-[(1-ethyl-4-piperidinyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-98-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3-aminophenyl)-1H-benzimidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705945-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN 705945-94-4 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN 705945-95-5 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705945-99-9 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-ylphenylmethylene]-1,3-dihydro-5-(4-piperidinylamino)-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-00-5 CAPLUS
CN Benzenecarboximidamide, 3-[(E)-1H-benzimidazol-2-yl][5-[(1-ethyl-4-piperidinyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-01-6 CAPLUS
CN 2H-Indol-2-one,
3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-[(1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 705946-62-7 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-ylphenylmethylene]-1,3-dihydro-5-[[2,2,6,6-tetramethyl-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAMES)

Double bond geometry as shown.



RN 705946-63-8 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl[3-methoxyphenyl]methylene]-5-[[1-ethyl-4-piperidinyl]amino]-1,3-dihydro-, (3Z)- (CA INDEX NAMES)

Double bond geometry as shown.



RN 705946-64-9 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl[3-chlorophenyl]methylene]-5-[[1-ethyl-4-piperidinyl]amino]-1,3-dihydro-, (3Z)- (CA INDEX NAMES)

Double bond geometry as shown.



RN 705946-23-8 CAPLUS
CN 1H-Imidazole-1,3(2H)-dione, 2-[2-[2-[(E)-[5-[(1-ethyl-4-piperidinyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]-1H-imidazol-5-yl]ethyl]-

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-15-0 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl[3-methoxyphenyl]methylene]-1,3-dihydro-5-[[5-[(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-16-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-17-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Double bond geometry as shown.



RN 705946-06-1 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-ylphenylmethylene]-5-[[1-[2-(dimethylamino)ethyl]-4-piperidinyl]amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-07-2 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-ylphenylmethylene]-1,3-dihydro-5-[[1-(methylsulfonyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-14-1 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl[3-chlorophenyl]methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-18-5 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl[3,5-difluorophenyl]methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-19-6 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl[3-chlorophenyl]methylene]-5-[[1-ethyl-4-piperidinyl]methylamino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-21-0 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl[4-chlorophenyl]methylene]-5-[[1-ethyl-4-piperidinyl]amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-22-5 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylene]-1,3-dihydro-5-[[1-(3-methoxypropyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-23-6 CAPLUS
CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylene]-1,3-dihydro-5-[[1-(3-methoxypropyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-24-7 CAPLUS
CN 2H-Indol-2-one,
3-[(3-chlorophenyl-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-2,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-25-8 CAPLUS
CN 2H-Indol-2-one, 5-[(3-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-26-9 CAPLUS
CN 2H-Indol-2-one,
3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 705946-27-0 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-28-1 CAPLUS
CN 2H-Indol-2-one,
3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-29-2 CAPLUS
CN 2H-Indol-2-one,
3-[(3-chloro-4-fluorophenyl)1H-Imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-30-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-31-2 CAPLUS
CN 2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)phenylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-32-3 CAPLUS
CN 2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Double bond geometry as shown.



RN 705946-33-4 CAPLUS
CN 2H-Indol-2-one, 5-[[1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-methylphenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-34-5 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(4-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-37-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)(6-fluoro-1H-benzimidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 705946-38-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)(6-fluoro-1H-benzimidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-35-6 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl(4-propylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-36-7 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 705946-39-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluoro-4-methylphenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-40-3 CAPLUS
CN 2H-Indol-2-one, 5-[[1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-41-4 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-(trifluoromethyl)phenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-42-5 CAPLUS
CN 2H-Indol-2-one,
3-[(4-chlorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-
4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-43-6 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-
methylphenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3E)-
(CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-
1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3E)- (CA
INDEX
NAME)

Double bond geometry as shown.



RN 705946-47-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-imidazol-2-yl[4-
(trifluoromethyl)phenyl]methylene]-5-[[1-(2-methoxyethyl)-4-
piperidinyl]amino]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-44-7 CAPLUS
CN 2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-3,3-dihydro-3-[(5-methyl-
1H-imidazol-2-yl)[6-(trifluoromethyl)-3-pyridinyl]methylene]-, (3E)- (CA
INDEX NAME)

Double bond geometry as shown.



RN 705946-45-8 CAPLUS
CN 2H-Indol-2-one,
1,3-dihydro-3-[1H-imidazol-2-yl(4-methylphenyl)methylene]-
5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-48-1 CAPLUS
CN 2H-Indol-2-one, 3-[[6-chloro-1H-benzimidazol-2-yl]phenylmethylene]-1,3-
dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX
NAME)

Double bond geometry as shown.



RN 705946-49-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[[1-
ethyl-4-piperidinyl]amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-50-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)(5-methyl-1H-imidazol-2-
yl)methylene]-5-[[1-ethyl-4-piperidinyl]amino]-1,3-dihydro-, (3Z)- (CA
INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Double bond geometry as shown.



RN 705946-51-6 CAPLUS
CN 2H-Indol-2-one, 3-[3,5-difluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-[2-methoxyethyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-52-7 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)(3-methyl-3H-imidazol-2-yl)methylene]-1,3-dihydro-3-[[1-[2-methoxyethyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-53-8 CAPLUS
CN 2H-Indol-2-one, 3-[3,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-[2-methoxyethyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-56-1 CAPLUS
CN 2H-Indol-2-one, 3-[3-chloro-4-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-[2-methoxyethyl)-4-piperidinyl]amino]-, (3E)- (CA INDEX
NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-53-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[[1-[2-methoxyethyl)-4-piperidinyl]amino]-3-[(5-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylene]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-54-9 CAPLUS
CN 2H-Indol-2-one, 3-[(4-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-[2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-57-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[(4-piperidinylamino)-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-58-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-[2-[1-piperidinyl)ethyl]-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-59-4 CAPLUS
CN 2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
5-[[[2-[4-morpholinyl]ethyl]-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-60-7 CAPLUS
CN 2H-Indol-2-one, 5-[[1-[2-(diethylamino)ethyl]-4-piperidinyl]amino]-3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-84-1 CAPLUS
CN 1H-Imidazole-4-propanoic acid,
2-[(Z)-[1,2-dihydro-5-[[1-(2-methoxyethyl)-
4-piperidinyl]amino]-2-oxo-3H-indol-3-ylidene](3-fluorophenyl)methyl]-4-methyl-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-85-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-2-ylphenylmethylene)-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-86-3 CAPLUS
CN 2H-Indol-2-one,
1,3-dihydro-3-[(H-imidazol-2-yl)(4-methoxyphenyl)methylene]-

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-61-8 CAPLUS
CN 2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
5-[[1-[2-(1-pyrrolidinyl)ethyl]-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-62-9 CAPLUS
CN 2H-Indol-2-one,
1,3-dihydro-3-[1H-imidazol-2-yl(4-methylphenyl)methylene]-
5-[[1-methyl-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-67-4 CAPLUS
CN 2H-Indol-2-one,
3-[(4-chlorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-68-5 CAPLUS
CN 2H-Indol-2-one, 3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-69-6 CAPLUS
CN 2H-Indol-2-one, 3-[(5-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(methylsulfonyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-70-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-imidazol-2-yl(4-propylphenyl)methylene]-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-73-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluoro-4-methylphenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-74-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-imidazol-2-yl[6-(trifluoromethyl)-3-pyridinyl]methylene]-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-71-0 CAPLUS
CN 2H-Indol-2-one, 5-[[1-ethyl-4-piperidinyl)amino]-3-[(7-fluorophenyl)(5-phenyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-72-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)(5-phenyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-76-5 CAPLUS
CN 2H-Indol-2-one, 5-[[1-ethyl-4-piperidinyl)amino]-3-[(2-fluoro-4-(trifluoromethyl)phenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-77-6 CAPLUS
CN 2H-Indol-2-one, 5-[[1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-78-7 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[[1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-79-8 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-

[trifluoromethyl)phenyl](5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-82-3 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(4-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-83-4 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-80-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-difluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-81-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chloro-4-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 705946-84-5 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluoro-4-

[trifluoromethyl)phenyl](5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-85-6 CAPLUS
CN 2H-Indol-2-one, 3-[(2,3-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-86-7 CAPLUS
CN 2H-Indol-2-one, 3-[(2,3-difluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-87-9 CAPLUS
CN 2H-Indol-2-one, 3-[2,4-difluorophenyl](5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-88-0 CAPLUS
CN 2H-Indol-2-one, 3-[(2,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-91-4 CAPLUS
CN 2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-1H-imidazol-2-yl)[3-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-92-5 CAPLUS
CN 2H-Indol-2-one, 3-[2,4-dichloro-5-fluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-89-1 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-90-3 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl[3-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-93-6 CAPLUS
CN 2H-Indol-2-one, 3-[(2,4-dichloro-5-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-94-7 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-2-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 704014-74-9 CAPLUS
CN 2H-Indol-2-one, 5-[8-azabicyclo[3.2.1]oct-3-ylamino)-3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



=>